Related Experiment Videos
[Helicobacter pylori and azithromycin]
F Mégraud1, V Darmaillac, D Brügmann
1Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux, France.
Pathologie-Biologie
|June 1, 1995
Summary
Helicobacter pylori, a stomach bacterium, causes ulcers and precancerous lesions. Tritherapy combining azithromycin, metronidazole, and omeprazole achieved 80% eradication in pilot trials.
Area of Science:
- Microbiology
- Gastroenterology
- Pharmacology
Background:
- Helicobacter pylori is a Gram-negative bacterium residing in the human stomach, transmitted via fecal-oral routes.
- It secretes cytotoxic compounds like urease and vacuolating cytotoxin, contributing to peptic ulcer disease and precancerous lesions.
- Current eradication strategies involve combining antisecretory drugs with antibiotics.
Purpose of the Study:
- To evaluate the efficacy of azithromycin in combination therapy for H. pylori eradication.
- To assess the pharmacokinetic profile of azithromycin in gastric tissue and mucus.
Main Methods:
- Determined azithromycin's Minimum Inhibitory Concentration (MIC50) and bactericidal activity.
- Measured azithromycin concentrations in gastric mucus and tissue after a 500 mg dose.
- Conducted pilot clinical trials using a triple therapy regimen.
Main Results:
- Azithromycin demonstrated potent activity with MIC50 at 0.12 mg/l and bactericidal activity at ≥0.10 mg/l.
- Achieved significant concentrations in gastric mucus (0.48 µg/g) and tissue (4 µg/g) with prolonged persistence due to a 3-day half-life.
- Pilot tritherapy (azithromycin, metronidazole, omeprazole) resulted in 80% H. pylori eradication.
Conclusions:
- Azithromycin exhibits promising activity against H. pylori.
- The combination therapy shows high eradication rates, warranting further validation in larger clinical trials.